Apr 21, 2021 02:17 PM (GMT+8) · EqualOcean
Today, Boya Jiyin, a biopharmaceutical enterprise, announced the completion of 400 million yuan B + round financing. This round of financing is led by zhengxingu capital, followed by Boyuan capital, Sherpa investment, etc., and followed by IDG capital, Lilly Asia Fund, Sanzheng health investment, Huagai capital, Sequoia Capital China fund, Yahui investment, Kunlun capital, etc. This round of financing funds will be used to continue to promote the clinical transformation of the company's product pipeline based on gene editing technology, and promote the company's industrial development.